MedTrace Logo

A Study of Actonel for the Prevention of Bone Loss

NCT00452439 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-12-28

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.

Conditions

Interventions

DRUG

Actonel (Risedronate)

35 mg (pill) by mouth weekly

DIETARY_SUPPLEMENT

Calcium

500 mg by mouth twice a day for a total of 24 months.

DIETARY_SUPPLEMENT

Vitamin D

400 IU by mouth twice a day for a total of 24 months.

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Maria E. Cabanillas, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452439 on ClinicalTrials.gov